A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RTA 1701 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs RTA 1701 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions; First in man
- Sponsors Reata Pharmaceuticals
- 02 Jul 2019 Status changed from recruiting to completed.
- 20 Jun 2018 According to a Reata Pharmaceuticals media release, initial results are expected in the first half of 2019.
- 20 Jun 2018 Status changed from planning to recruiting, according to a Reata Pharmaceuticals media release.